Molecular Insight Pharmaceuticals Inc.

Donald E. Wallroth has served as our Chief Financial Officer since 2007 and has more than 25 years of financial and operating experience working with high growth technology companies. Mr. Wallroth joined Molecular Insight from the National Life Sciences practice of Tatum LLC, a national financial executive services firm, where he was Partner and was deployed as the CFO for prominent New England-based companies. Prior to joining Tatum LLC, Mr. Wallroth was a Partner with Keen Partners, an investment banking firm with a focus on the life sciences, among other industries. Before joining Keen Partners, he served as Chief Operating Officer of GoldK, where he managed financial activities and business operations. Prior to GoldK, Mr. Wallroth was the Chief Financial Officer and Chief Operating Officer of Transition Systems, a healthcare software company. In addition, he served as Chief Financial Officer of Project Software and Development, Inc. (PSDI), subsequently called MRO Software, Inc., which was recently acquired by IBM. Mr. Wallroth also served as a Partner at Accenture and a Partner at Arthur D. Little, Inc. Mr. Wallroth received an MBA from the Columbia University Graduate School of Business and a Bachelor of Science in Electrical Engineering from The George Washington University.

Norman LaFrance, M.D., FACP, FACNP has served as our Senior Vice President, Clinical Development and Chief Medical Officer since April 2007. He has more than 20 years of experience in the pharmaceutical and healthcare industry, including drug development and commercialization work with molecular imaging and therapeutic companies. His background includes strategic planning and management of pharmaceutical development for FDA approval as well as clinical and academic experience. From 2005 to 2007 he worked at Bausch & Lomb, where he served as Vice President, Global Pharmaceutical R&D. Dr. LaFrance was with Celltech Americas as Senior Vice President, Medical and Regulatory Affairs from 2002 to 2005, where he held responsibility for Clinical Research, Clinical Operations, Medical Affairs (including Pharmacovigilance, Medical Education & Medical Information) and Regulatory Affairs & Operations. Additionally, he held positions of increasing responsibility at Bracco Diagnostics Inc. and at Sterling Winthrop Pharmaceuticals. Dr. LaFrance began his industry career at DuPont Merck Pharmaceutical Company where he was instrumental in Cardiolite, Neurolite and Persantine programs. Previously, he practiced medicine and held academic appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. Dr. LaFrance received a B.S. degree and Masters Degree in Nuclear Engineering & Science from Renssalaer Polytechnic Institute, and an M.D. degree from the University of Arizona. He is Board-certified in Internal Medicine and Nuclear Medicine and is a Fellow in the American College of Physicians and the American College of Nuclear Physicians.

John A. Barrett, Ph.D. has served as our Vice President of Nonclinical Development since August 2005. He has over 20 years of experience in the discovery and development of agents in oncology and angiogenesis-directed tumor imaging and therapy. He came to Molecular Insight from Infinity Pharmaceuticals where he worked from 2003 to 2005 and served as the Senior Director Pharmacology/ Toxicology, ADME, and Bioanalytical Chemistry. Prior to Infinity Pharmaceuticals, Dr. Barrett was Senior Director of Pharmacology/ Toxicology at EPIX Medical, Inc. from 2000 to 2003. In 1993, Dr. Barrett was recruited to DuPont Merck Radiopharmaceutical Division as a Principal Research Scientist in Biological Research Imaging, and later was appointed as Director Discovery Biology Research Imaging and Animal Resources. He has held positions at Rorer Pharmaceuticals where he was Group Leader of Cardiovascular Pharmacology and as Research Manager in Vascular Biology at the RWJ Pharmaceutical Research Institute. Dr. Barrett received a B.S. from the State University of New York at Oneonta and a Ph.D. from St. John's University.

Brian Abeysekera, Ph.D. has served as our Vice President, Manufacturing since April 2007. He has more than 20 years of experience in radioisotope and radiopharmaceutical development, including production, radiochemistry, quality control, quality assurance and regulatory affairs activities in the United States and Canada. From 1985 to 2007, he worked at MDS Nordion, where he held various positions, including Manager Radiopharmaceutical Development; Director, Quality Safety and Regulatory Affairs; and most recently, Director, Applied R&D. During his tenure at Nordion, Dr. Abeysekera helped establish the company as a cGMP supplier of sterile pharmaceuticals in the United States and Canada; designed, developed and validated aseptic manufacturing facilities; directed scale-up from clinical to commercial manufacturing; and developed chemistry and manufacturing sections for numerous small molecule and biologic products to support FDA submissions. Dr. Abeysekera holds a Ph.D. in synthetic organic chemistry from the University of British Columbia.

James F. Kronauge, Ph.D. has served as our Vice President of Process Chemistry since August 2005. He joined the company in December 1999. He has been an active researcher in the field of radiology and nuclear medicine for the past 20 years and has published more than 50 research articles in a variety of peer-reviewed journals. He is inventor or co-inventor of six issued patents, including one for the use of Cardiolite, a perfusion imaging agent for the detection of cardiac ischemia. Prior to joining Molecular Insight, he was Assistant Professor of Radiology at Harvard Medical School and Associate Director of Radiopharmacy in the Joint Program in Nuclear Medicine at Brigham and Women’s Hospital, Boston, Massachusetts. His research efforts have focused on the development of diagnostic agents for measurement of tissue perfusion in cardiovascular disease, developing imaging agents for the detection of various cancers and monitoring multi-drug resistance in tumors. His experience includes synthetic organic and inorganic chemistry, elucidation of drug interactions by in vitro cell culture techniques and in vivo animal models, HPLC analysis, pharmacodynamics and metabolism studies, radiochemistry and pharmaceutical chemistry. He has been involved with the discovery and development of CardioGen (Bracco) and Mebrofennin (Bracco). Dr. Kronauge received a B.S in Chemistry from the University of Cincinnati, and a Ph.D. in Inorganic Chemistry from M.I.T. under the guidance of Professor Alan Davison.

James Wachholz has served as our Vice President, Regulatory Affairs and Quality Assurance since May 2005. He has over 20 years of experience in regulatory affairs and product development at biotechnology and pharmaceutical companies. From 2003 to May 2005, he worked at Accentia Biopharmaceuticals, where he served as Chief Regulatory Officer. From 1998 to 2003 Mr. Wachholz worked at Sepracor Inc., where he served as the Executive Director of Regulatory Affairs. Previously, Mr. Wachholz held regulatory and compliance positions at Hybridon, Inc., Searle Pharmaceuticals and Baxter International. Mr. Wachholz received a B.S. in Biochemistry from Northern Illinois University and an M.B.A. from DePaul University.

John L. Joyal, Ph.D. has served as our Vice President of Discovery Research since January of 2008. He joined Molecular Insight as Director of Biology in 2005. He has more than 20 years of oncology basic research and drug discovery experience with expertise in cell and molecular biology, particularly in the areas of receptor biology, signal transduction pathways and assay development. Prior to joining Molecular Insight, Dr. Joyal was Director of Discovery Research at Phylogix Pharmaceuticals where he led a team evaluating the biology and mechanism of action of protein therapeutics for oncology supportive care. From 1997 to 2004, he held several positions at Praecis Pharmaceuticals, including Director of Cell Biology, where he initiated or contributed to the establishment of numerous research projects focusing on the discovery of novel therapeutics for the treatment of cancer, inflammation, infectious disease and neurological disorders. From 1993 to 1997, Dr. Joyal did his post-doctoral training at Harvard Medical School/Brigham and Women’s Hospital examining novel interactions between the calcium sensor, calmodulin and proteins involved in breast carcinogenesis and growth factor signaling. He received his Ph.D. in biology in 1994 from Tufts University studying mitochondrial physiology.

Paul H. Granger, Vice President and General Counsel, has for over 25 years provided legal counsel to U.S. and international companies. Most recently, he served as Counsel with Greenberg Traurig LLP, the 7th largest U.S. law firm. At Greenberg Traurig, Mr. Granger practiced in the corporate/securities area, primarily advising clients in life science and high technology industries. Prior to that, he provided legal and business counsel to small and mid-size companies, including an early-stage pharmaceutical products development firm. Mr. Granger advised on regulatory compliance, clinical trials, intellectual property protection, manufacturing, supply/distribution strategy, and general business matters. Mr. Granger also served as Vice President and Assistant Secretary of Arthur D. Little, Inc., where he was in charge of global contracting. Mr. Granger received a B.A. from Clark University and a J.D. from Suffolk University Law School.

Wendy Graham-Coco has served as our Vice President of Program Management since January of 2008 and has been an integral member of the Molecular Insight Research and Development team for more than a decade. She has more than 20 years of research experience, including 16 years in discovery research, of which seven were in academic drug discovery at the Massachusetts General Hospital in Boston, MA. She has experience managing various phases of drug development, including preclinical development, early clinical development and manufacturing. Ms. Graham-Coco is currently General Manager for the Azedra program. Prior to her tenure as Vice President at Molecular Insight, Ms. Graham-Coco served in various roles in Program Management, Operations and Business Development. She earned a B.A. in Biology, Pre-Med at Boston University and her M.B.A. from Simmons Graduate School of Management.

Anthony F. Martin, Ph.D., was elected Molecular Insight’s Non-Executive Chairman of the Board in February 2009. A member of the Board since September 2008, he has more than 20 years’ experience in providing life science and biotechnology companies counsel on a range of strategic, management and funding issues. Dr. Martin is the Founder and Managing Partner of TMA Consultants, an organization that specializes in providing business planning and interim management for biotechnology companies. Dr. Martin has most recently served as Non-Executive Director of Prelude Trust plc, an investment trust that specialized in early-stage, technology-based businesses; and as Chairman of NeuTec Pharma plc, playing a pivotal role in guiding the biopharmaceutical company’s listing on the AIM market in the United Kingdom and its subsequent sale to Novartis. Dr. Martin has also held senior positions in a number of well-known life science businesses both in the United Kingdom and United States including: Managing Director of British Biotech Products Ltd, Chairman, President and CEO of Molecular Probes, President of Molecular Biology, Invitrogen Corporation, Chairman and CEO of AZUR Environmental, CEO of Celsis International plc, as well as senior leadership roles at Amersham International plc. Dr. Martin holds a Ph.D. in Immunology and a first class honors degree in Applied Chemistry from the Universities of Manchester and Huddersfield, UK. In addition, Dr. Martin is currently Chairman of Sphere Medical Holdings plc, Wound Solutions Ltd. and Safeguard Biosystems Holdings Ltd.

Daniel Frank has served as a member of our Board of Directors since 2004. Since 2001, he has worked at Cerberus Capital Management, L.P., a private investment firm. From 1999 to 2001, Mr. Frank served as a Managing Director and Portfolio Manager of ACI Capital Strategic Fund, a New York-based hedge fund, and prior to that he served as a portfolio manager for Chatterjee/ Soros Fund Management. From 1979 to 1996, Mr. Frank was employed by Fidelity Management and Research (Fidelity Investments). While at Fidelity, Mr. Frank served as Assistant Portfolio Manager to Peter Lynch on the Magellan Fund and as Vice President and sole Portfolio Manager, for over a decade, of the Fidelity Strategic Opportunities/ Special Situations Fund. In 1996, Mr. Frank was ranked by Barron's magazine as one of the Top 100 U.S. Mutual Fund Managers. Mr. Frank served on the Board of Directors of i-STAT Corporation from 2001 until its sale to Abbott Laboratories in 2003. From 1986 until its sale in 1996, Mr. Frank was board member and largest stockholder of Corsearch, a New York-based trademark research firm that is now part of CCH-Wolters Klower Inc. Mr. Frank received a B.S. in Business Administration from Boston University School of Management.

Daniel L. Peters was appointed President and Chief Executive Officer of Molecular Insight Pharmaceuticals on May 13, 2009. He was also elected to the Board of Directors. Most recently he served as President and Chief Executive Officer of the Medical Diagnostics business of GE Healthcare. GE Medical Diagnostics develops, manufactures and markets a broad portfolio of diagnostic pharmaceuticals, including radiopharmaceuticals that are used to provide early health information in cardiology, oncology, neurology and urology. Mr. Peters had responsibility for all aspects of the business including, but not limited to, the global P&L, long-term growth strategies, marketing, sales, business development, R&D and manufacturing. During his tenure with the unit, annual revenues grew, on average, at 10 percent. As CEO, Mr. Peters was actively involved in the development of the growth strategies for expansion of the business beyond its then-current portfolio. Under his leadership, the radiopharmaceutical business of Amersham Health was also successfully integrated into GE Healthcare, taking the more descriptive name of Medical Diagnostics. Prior to joining GE Healthcare, Mr. Peters had been Chief Operating Officer of Amersham Health where he had worldwide operational responsibilities for all aspects of the business. While at Amersham and in addition to his regular operational duties, Mr. Peters played a key role in recruiting new talent to strengthen the R&D organization and in reorganizing the business structure to place more focus on emerging markets. Earlier in his career, Mr. Peters was President of Nycomed Amersham, Inc., a $500 million North and South America diagnostic and therapeutic pharmaceutical subsidiary of Amersham Plc. of the U.K. Mr. Peters also served as President of Nycomed, Inc. and held executive positions of increasing responsibility including the role of President of the U.S. pharmaceuticals business for Sanofi Winthrop Pharmaceuticals. In each of Mr. Peters' roles, he has successfully built teams that effectively work across all segments of the business, forging strong working units focused on operational success, delivering results and value creation. Mr. Peters' experience in developing business strategies, assessing market opportunities, launching new products and structuring companies for growth will serve Molecular Insight well as the Company moves into its next stage of product development, strategic partnering and product launch. Mr. Peters, who holds a bachelor's degree from Western Illinois University, is currently Chairman of the Board of Phadia AB, and also serves on the boards of MDRNA, Inc. He also has been a member of the boards of the Healthcare Institute of New Jersey and the Pharmaceutical Researchers and Manufacturers of America.

David R. Epstein has served as a member of our Board of Directors since September 2008 and has had more than 20 years of extensive executive experience in the Pharmaceutical sector. He is currently President and Chief Executive Officer of Novartis Oncology and is responsible for leading Novartis' Global Oncology Business Unit, one of the world's top Oncology companies with six key marketed products and a leading pipeline. He is also a member of Novartis AG's Pharma Committee and Pharmaceutical Executive Committee. Mr. Epstein has held a series of positions of increasing responsibility since joining the company in 1989. Mr. Epstein previously served as Chief Executive Officer, Novartis Specialty Medicines, overseeing the global Ophthalmics and Transplantation and Immunology Business Units in addition to his responsibilities leading Novartis Oncology. He also served as Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States in addition to several previous commercial roles. Prior to joining Novartis, he was an associate in the Strategy Practice of consulting firm Booz, Allen and Hamilton. Mr. Epstein holds a B.S. degree in Pharmacy from Rutgers University College of Pharmacy and an M.B.A. in Finance and Marketing from the Columbia University Graduate School of Business.

David S. Barlow has served as a member of our board of directors since 2000. Since March 2000 Mr. Barlow has served as Chairman of Molecular Insight Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on developing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics for cancer, and as Chief Executive Officer since December 2002. From 1995 to September 1999, Mr. Barlow was President of Pharmaceuticals at Sepracor, Inc., a research-based pharmaceutical company. From 1993 to 1995, Mr. Barlow served as the General Manager of Pharmaceuticals at Sepracor, Inc. Prior to 1993, Mr. Barlow held several senior level positions at Rhone-Poulenc Rorer, Inc., pharmaceutical company, including Vice President, World Wide Marketing and Business Development at Armor Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer, Inc. Mr. Barlow serves on the Board of Trustees of Bates College, McLean Hospital and Newton Country Day School.

Dr. Harry Stylli has a track record of nearly two decades demonstrating entrepreneurial leadership in the biotechnology and pharmaceutical industries, and has broad experience in successfully translating innovative technology into commercial opportunities. Dr. Stylli was appointed President and Chief Executive Officer of Sequenom, Inc. and was elected to the Board of Directors in June 2005. Most recently, he served as President and Chief Executive Officer of Xencor, Inc., a privately held biotechnology company. Previously, Dr. Stylli was President and CEO of CovX Pharmaceuticals, a newly founded company that he assisted in securing key financing through a revised and focused business plan, launch of a development pipeline, and building a discovery/pre-clinical organization. Dr. Stylli co-founded Aurora Biosciences in 1995. As Senior Vice President of Screening Technology and New Ventures, he helped raise venture and public capital, led the creation and development of their core platform, and played a pivotal role in generating groundbreaking alliances with pharmaceutical companies resulting in over $300 million in committed capital. In 1999, Dr. Stylli assumed the role of Senior Vice President of Commercial Development, built a business organization that grew the Aurora 's revenues to approximately $95 million while netting $13 million by 2001, and ultimately facilitated Aurora 's transition from a technology to an integrated drug discovery company. In 2001 he was key to the success of Aurora 's acquisition by Vertex Pharmaceuticals for over $600 million. Following the merger, Dr. Stylli maintained P&L responsibility as President of Aurora Biosciences and Panvera. From 1987 to 1995, Dr. Stylli held various positions of increased responsibility in the global discovery organization of GlaxoSmithKline. Dr. Stylli currently serves as a Director of Molecular Insight Pharmaceuticals, Inc., a privately held biotechnology company, and is an advisor to Nanosyn, a private medicinal chemistry company. He received his bachelor's of science degree from the University of East London, United Kingdom and his Ph.D. from London University 's Faculty of Medicine. He later earned his master's of business administration from the U.K's Open University.

Lionel Sterling was appointed to the Third Wave board of directors in August 2004. Mr. Sterling is president of Equity Resources, Inc., a private investment firm. He previously co-founded and served as managing partner of the private investment firm Whitehead/Sterling. Mr. Sterling served most recently on the board of directors of i-STAT Corp., a leading point-of-care diagnostics company, until its sale to Abbott Laboratories. He also has served as chairman of the board of directors of Rayovac Corp., Executive Vice President and Director of United Brands Co., and Sector Executive and Chief Financial Officer of American Can Co. He also held various investment and financial positions at Donaldson, Lufkin & Jenrette Inc. and ITT Corp. Mr. Sterling holds an MBA from New York University.

Scott Gottlieb, M.D., has served as a member of our Board of Directors since 2007. Dr. Gottlieb, a practicing physician, joined the American Enterprise Institute earlier this year after several years at the U.S. Food and Drug Administration (FDA). Dr. Gottlieb was the Deputy Commissioner for Medical and Scientific Affairs at the FDA from 2005 to 2007. Prior to his appointment as Deputy Commissioner, he served at the FDA in a number of senior capacities, including Senior Advisor for Medical Technology for the FDA Commissioner and Director of Medical Policy Development. During his time in government, he also served as Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS), and is a frequent contributor to leading journals and publications. Dr. Gottlieb is a Partner at Arcoda Capital and a Venture Partner at New Enterprise Associates. He received his M.D. degree from the Mount Sinai School of Medicine in New York and his B.A. degree in economics from Wesleyan University in Middletown, Connecticut.

Yvonne Greenstreet, M.D. has served as a member of our Board of Directors since September 2008 and has more than 16 years of Pharmaceutical Industry experience in medicines development, medical affairs and business development. She is currently Senior Vice President and Chief of Strategy, R&D at GlaxoSmithKline where she is responsible for leading strategy development and driving the transformation of Research and Development to address evolving healthcare needs. She is also a member of the GlaxoSmithKline's Global Product Management Board and the Research and Development Executive Committee. Prior to her current role, Dr. Greenstreet was Senior Vice President and Head of the Musculoskeletal, Inflammation Gastrointestinal & Urogenital Medicine Development Centre at GlaxoSmithKline (GSK) where she defined pipeline strategy and built a promising portfolio, successfully inlicensing several clinical stage assets as well as bringing three new significant medicines to market. Previously, Dr. Greenstreet served as Vice President and Head of European Clinical Development and Medical Affairs, and as Chief Medical Officer of GSK in Europe, where she was responsible for the development and delivery of European phase II-IV clinical plans, studies and submissions. Dr. Greenstreet was also Vice President and Medical Director for Pharmaceutical business in the UK, where she also served on the Advisory Committee for Topic Selection for NICE, the Association of the British Pharmaceutical Industry Medical Committee and the Prescription Medicines Code of Practice Authority Appeal Board. Dr. Greenstreet graduated in medicine from the University of Leeds, and studied at several London teaching hospitals including St. Thomas', St. Mary's University College and St. Bartholomew's. She obtained an M.B.A from INSEAD, France.